🇺🇸 FDA
Company

REGENERON

REGENERON PHARMACEUTICALS, INC.

REGN pharma USA

Quick answer

REGENERON is a pharma company (REGN) headquartered in TARRYTOWN, NY, USA with 24 tracked pipeline programs.

Pipeline (24)

project

2-mg Intravitreous Aflibercept Injection

Proliferative Diabetic Retinopathy

Phase 3 · small_molecule · completed

1 trials project

2.0 mg intravitreal aflibercept

Diabetic Macular Edema

Phase 3 · small_molecule · completed

1 trials project

8 mg aflibercept (BAY 86-5321) (High Dose)

Diabetic Macular Edema

Phase 3 · small_molecule · completed

1 trials project

Aflibercept

Prostatic Neoplasms

Phase 3 · small_molecule · completed

1 trials project

Aflibercept

Colorectal Cancer Metastatic

Phase 3 · small_molecule · completed

3 trials project

Aflibercept (EYLEA, BAY86-5321)

Glaucoma, Neovascular

Phase 3 · small_molecule · completed

1 trials project

Aflibercept (Eylea, BAY 86-5321)

Glaucoma, Neovascular

Phase 3 · small_molecule · completed

1 trials project

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Macular Edema

Phase 3 · mab · completed

1 trials project

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Macular Degeneration

Phase 3 · mab · completed

1 trials project

Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Pancreatic Neoplasm

Phase 3 · small_molecule · terminated

1 trials project

Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Carcinoma

Phase 3 · small_molecule · completed

1 trials project

Aflibercept 8 mg

Neovascular Age-Related Macular Degeneration

Phase 3 · small_molecule · active

1 trials project

Aflibercept AVE0005

Colorectal Cancer Metastatic

Phase 3 · small_molecule · terminated

2 trials project

Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Neovascular Age-Related Macular Degeneration

Phase 3 · small_molecule · completed

1 trials project

Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

Retinal Vein Occlusion

Phase 3 · mab · completed

1 trials project

Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

Macular Edema Secondary to Retinal Vein Occlusion

Phase 3 · small_molecule · completed

1 trials project

Alirocumab

Coronary Vessel

Phase 3 · small_molecule · completed

1 trials project

Alirocumab

Homozygous Familial Hypercholesterolemia

Phase 3 · small_molecule · completed

1 trials project

Alirocumab

Type2 Diabetes

Phase 3 · small_molecule · completed

1 trials project

Alirocumab

Atherosclerotic Cardiovascular Disease

Phase 3 · small_molecule · completed

1 trials project

Alirocumab

Hypercholesterolaemia

Phase 3 · small_molecule · completed

2 trials project

Alirocumab

Hypercholesterolemia

Phase 3 · small_molecule · active

18 trials project

Alirocumab 150 MG/ML [Praluent]

Hemodialysis

Phase 3 · small_molecule · active

1 trials project

Alirocumab SAR236553

Hypercholesterolaemia

Phase 3 · small_molecule · completed

1 trials

Drugs (7)

drug

aflibercept

EYLEA

 drug

alirocumab

PRALUENT

 drug

atoltivimab

INMAZEB

 drug

cemiplimab-rwlc

LIBTAYO

 drug

dupilumab

DUPIXENT

 drug

evinacumab-dgnb

EVKEEZA

 drug

pozelimab-bbfg

VEOPOZ

Patents (8)

patent

US 12421512

CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or ag

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12421315

CLL-1 targeted immunotherapies

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12419963

Diels-Alder conjugation methods

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12421317

Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonis

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12415856

EGFR x CD28 multispecific antibodies

Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12410442

Compositions and methods for treating sensorineural hearing loss using otoferlin

Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12404505

Delivery of a gene-editing system with a single retroviral particle and methods

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12402611

Genetically modified mice and engraftment

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)